18.01.2013 • NewsMomentiveMSC AustraliaDynea Chemical

Momentive Acquires Interest in Dynea Australia Joint Venture with Laminex

Momentive Specialty Chemicals today announced that Momentive Specialty Chemicals ("MSC Australia"), a wholly owned subsidiary of the company, has acquired Dynea Chemical's interest in the Dynea Australia joint venture with the Laminex Group. The new joint venture, known as Momentive Specialty Chemicals Australia ("JV"), is owned 50% by Momentive Specialty Chemicals and 50% by Laminex.

The JV provides formaldehyde and urea formaldehyde resins to Laminex, as well as other products to industrial customers in Western Australia. MSC Australia will manage the day-to-day operations of the JV, as well as provide industry leading technology to the JV. Laminex is a marketer and manufacturer of decorative surfaces in Australia and New Zealand. Laminex also produces raw wood panels, a vital product for decorative surfaces.

The JV, which has 30 employees, generated approximately $30 million in sales in 2011. Terms of the transaction were not disclosed

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.